In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $9.00.
Justin Walsh has given his Buy rating due to a combination of factors including the promising potential of Actimab-A as a foundational therapy in acute myeloid leukemia (AML). The optimism expressed by Dr. Ehab Atallah regarding Actimab-A’s role in combination therapies aligns with Walsh’s own projections, which estimate significant peak sales in the U.S. market. Additionally, the anticipated data readouts for Actimab-A and Iomab-ACT in 2025 are expected to be pivotal in demonstrating the clinical and regulatory success of Actimab-A, particularly in light of past challenges faced by Iomab-B.
Furthermore, Actinium Pharmaceuticals’ strategic collaborations, such as the Cooperative Research and Development Agreement with the National Cancer Institute, bolster the development of Actimab-A. The planned Phase I and Phase II/III trials, along with potential partnerships, are crucial steps forward. The trials aim to explore Actimab-A in combination with other treatments, such as venetoclax and ASTX-727, and the company is also investigating its use in other cancers, which could enhance its efficacy and broaden its application. These developments contribute to the positive outlook and justify the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.